Sugi Predict

Sugi Predict / Compounds / SCHEMBL1832383

SCHEMBL1832383

SCHEMBL1832383

CCOP(=O)(Cc1cccc(C(F)(F)F)c1)OCC

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ACP3 P15309 1/20 0.60
▸ PGK1 P00558 1/20 0.48
▸ PGK2 P07205 1/20 0.48
▸ IDO1 P14902 2/20 0.47
▸ HTR2A P28223 2/20 0.46
▸ HTR2B P41595 2/20 0.46
▸ HTR2C P28335 1/20 0.46
▸ LMNA P02545 3/20 0.45
▸ NPSR1 Q6W5P4 2/20 0.45
▸ GAA P10253 2/20 0.45
▸ KMT2A Q03164 2/20 0.45
▸ MEN1 O00255 1/20 0.45
▸ TAAR1 Q96RJ0 1/20 0.45
▸ MAPT P10636 3/20 0.44
▸ SIGMAR1 Q99720 1/20 0.44
▸ ADRA2C P18825 1/20 0.44
▸ SLC6A4 P31645 1/20 0.44
▸ ADRA1A P35348 1/20 0.44
▸ DRD3 P35462 1/20 0.44
▸ OPRK1 P41145 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29427108 1.00 ACP3 (0.60) ACP3PGK1PGK2IDO1HTR2A
SCHEMBL8957011 0.92 ACP3 (0.55) ACP3PGK1PGK2IDO1HTR2A
SCHEMBL8957013 0.90 ACP3 (0.50) ACP3PGK1PGK2IDO1HTR2A
SCHEMBL8957047 0.88 ACP3 (0.48) ACP3PGK1PGK2IDO1HTR2A
SCHEMBL8957026 0.88 ACP3 (0.48) ACP3PGK1PGK2IDO1HTR2A
SCHEMBL8956972 0.87 ACP3 (0.68) ACP3PGK1PGK2IDO1HTR2A
SCHEMBL8957015 0.85 ACP3 (0.57) ACP3PGK1PGK2IDO1HTR2A
SCHEMBL8957041 0.85 ACP3 (0.48) ACP3PGK1PGK2IDO1HTR2A
SCHEMBL8957056 0.84 IDO1 (0.42) ACP3IDO1LMNANPSR1GAA
SCHEMBL3390402 0.84 CCNT1 (0.46) NPSR1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-5532226-A FOR INCREASING BONE FORMATION AND BONE MASS IN MAMMALS ORTHO PHARMACEUTICAL CORPORATION (US) 1996-07-02 — — US claimed
EP-0524023-A1 Trifluoromethylbenzylphosphonates useful in treating osteoporosis ORTHO PHARMACEUTICAL CORPORATION (US) 1993-01-20 — — EP claimed
EP-4570313-A2 CYANOTRIAZOLE COMPOUNDS Otsuka Pharmaceutical Co., Ltd. (JP) 2025-06-18 — — EP disclosed
EP-4217062-B1 CYCLOBUTYL AMIDE MONOACYLGLYCEROL LIPASE MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2024-10-09 — — EP disclosed
US-20240208902-A1 CYCLOBUTYL AMIDE MONOACYLGLYCEROL LIPASE MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2024-06-27 — — US disclosed
WO-2024059317-A1 YAP/TAZ-TEAD ONCOPROTEINS INHIBITORS BRIDGENE BIOSCIENCES, INC. (US) 2024-03-21 — — WO disclosed
US-11802111-B2 Cyclobutyl amide monoacylglycerol lipase modulators JANSSEN PHARMACEUTICA NV (BE) 2023-10-31 — — US disclosed
EP-4217062-A1 CYCLOBUTYL AMIDE MONOACYLGLYCEROL LIPASE MODULATORS JANSSEN Pharmaceutica NV (BE) 2023-08-02 — — EP disclosed
EP-4219477-A1 CYANOTRIAZOLE COMPOUNDS Otsuka Pharmaceutical Co., Ltd. (JP) 2023-08-02 — — EP disclosed
WO-2022063784-A1 CYCLOBUTYL AMIDE MONOACYLGLYCEROL LIPASE MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2022-03-31 — — WO disclosed
US-20220089538-A1 CYCLOBUTYL AMIDE MONOACYLGLYCEROL LIPASE MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2022-03-24 — — US disclosed
US-20100041686-A1 4,5-DIHYDRO-OXAZOL-2YL DERIVATIVES HOFFMANN-LA ROCHE, INC. 2010-02-18 — — US disclosed
US-20100029589-A1 4,5-DIHYDRO-OXAZOL-2YL DERIVATIVES HOFFMANN-LA ROCHE INC. 2010-02-04 — — US disclosed
WO-2010010014-A1 4,5-DIHYDRO-OXAZOL-2-YL DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2010-01-28 — — WO disclosed
US-5532226-A FOR INCREASING BONE FORMATION AND BONE MASS IN MAMMALS ORTHO PHARMACEUTICAL CORPORATION (US) 1996-07-02 — — US disclosed
US-5300687-A Trifluoromethylbenzylphosphonates useful in treating osteoporosis ORTHO PHARMACEUTICAL CORPORATION (US) 1994-04-05 — — US disclosed
EP-0524023-A1 Trifluoromethylbenzylphosphonates useful in treating osteoporosis ORTHO PHARMACEUTICAL CORPORATION (US) 1993-01-20 — — EP disclosed
EP-0144640-B1 DISTYRENE COMPOUNDS BAYER AG (DE) 1986-09-17 — — EP disclosed
US-4610807-A FLUORESCENT BRIGHTENERS BAYER AKTIENGESELLSCHAFT (DE) 1986-09-09 — — US disclosed
EP-0144640-A1 Distyrene compounds BAYER AG (DE) 1985-06-19 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100029589-A1 4,5-DIHYDRO-OXAZOL-2YL DERIVATIVES NPY5R, NPY1R, NPY4R ACP3 2910/4885PGK1 1857/4885PGK2 2008/4885
US-20100041686-A1 4,5-DIHYDRO-OXAZOL-2YL DERIVATIVES NPY5R, NPY1R, NPY4R ACP3 2910/4885PGK1 1857/4885PGK2 2008/4885
US-20240208902-A1 CYCLOBUTYL AMIDE MONOACYLGLYCEROL LIPASE MODULATORS MGLL, LPL, PNLIP ACP3 1090/4885PGK1 1351/4885PGK2 1512/4885
US-20220089538-A1 CYCLOBUTYL AMIDE MONOACYLGLYCEROL LIPASE MODULATORS MGLL, LPL, PNLIP ACP3 1073/4885PGK1 1335/4885PGK2 1472/4885
US-11802111-B2 Cyclobutyl amide monoacylglycerol lipase modulators MGLL, LPL, PNLIP ACP3 1073/4885PGK1 1335/4885PGK2 1472/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.